Reneo Pharmaceuticals Announces Stockholder Approval for Merger with OnKure

Reneo Pharmaceuticals has announced that its stockholders have approved the merger with OnKure. This significant development paves the way for the integrated company to advance its mission in the pharmaceutical industry. The merger will combine the strengths of both organizations, enabling enhanced research and development efforts. Following the approval, Reneo aims to streamline operations and leverage combined expertise to drive innovation and growth in the market. Further details regarding the merger’s impact on Reneo’s strategic initiatives will be shared in upcoming communications.